Study of AL8326 plus Toripalimab for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two drugs (AL8326 and Toripalimab) for people with advanced solid tumors that have stopped responding to standard treatments or have no other options. The goal is to see if the combination is safe and shrinks tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have an advanced solid tumor that has come back, spread, or cannot be removed, and standard treatments have stopped working or are not available.
- You must have at least one tumor that can be measured on scans (like a CT scan).
- You must be in generally good health, as measured by your ability to perform daily activities (ECOG score 0 or 1).
- You must have normal kidney, liver, and bone marrow function based on blood tests.
- You must not be pregnant or breastfeeding, and if you or your partner can have children, you must use effective birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two investigational drugs, WX390 and Toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This Phase 2 trial studies toripalimab (JS001), given alone, in people whose tumors have specific POLE or POLD gene mutations but do not have MSI-H/dMMR. If it works, it may help shrink or control advanced solid tumors that have not responded to standard treatment.
This trial tests a new combination of two drugs (LTC004 and toripalimab) for people with advanced solid tumors that have stopped responding to standard immunotherapy. It aims to see if this combination can help when immunotherapy alone no longer works.
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.